Scarica l'app Stockscreener
0.6614
0.06%
0.0004
Precedente Chiudi:
$0.661
Aprire:
$0.67
Volume 24 ore:
186.02K
Relative Volume:
0.63
Capitalizzazione di mercato:
$89.88M
Reddito:
-
Utile/perdita netta:
$-112.46M
Rapporto P/E:
-0.4033
EPS:
-1.64
Flusso di cassa netto:
$-99.89M
1 W Prestazione:
-8.13%
1M Prestazione:
+4.32%
6M Prestazione:
-17.82%
1 anno Prestazione:
-62.42%
Intervallo 1D:
$0.6614
$0.6929
Intervallo di 1 settimana:
$0.6505
$0.743
Portata 52W:
$0.49
$1.87
Vor Biopharma Inc Stock (VOR) Company Profile
Nome
Vor Biopharma Inc
Settore
Industria
Telefono
617-655-6580
Indirizzo
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Confronta VOR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
0.6614 | 89.88M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-26 | Iniziato | Wedbush | Outperform |
| 2022-04-27 | Iniziato | Goldman | Neutral |
| 2021-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-03 | Iniziato | Robert W. Baird | Outperform |
| 2021-12-02 | Iniziato | Oppenheimer | Outperform |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-03-25 | Iniziato | B. Riley Securities | Buy |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-03-03 | Iniziato | Evercore ISI | Outperform |
| 2021-03-02 | Iniziato | Goldman | Sell |
| 2021-03-02 | Iniziato | Stifel | Buy |
Mostra tutto
Vor Biopharma Inc Borsa (VOR) Ultime notizie
Crescent Biopharma Appoints David Lubner to Board of Directors - The Manila Times
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML) - The Globe and Mail
Vor Biopharma faces Nasdaq delisting over low stock price - Investing.com
Vor Biopharma faces Nasdaq delisting over low stock price By Investing.com - Investing.com Nigeria
Vor Biopharma Inc’s Market Journey: Closing Strong at 0.70, Up 2.27 - DWinneX
Vor Biopharma Inc. (NYSE:VOR) Receives Average Recommendation of “Buy” from Analysts - Defense World
Shares Of Vor Biopharma Inc (NASDAQ: VOR): Are They Overvalued Compared To Others? - Stocksregister
INVESTOR ALERT: Cohen Milstein Calls on Zenas BioPharma - GlobeNewswire
Vor Biopharma stock plunges to 52-week low of $0.5 By Investing.com - Investing.com Canada
Vor Biopharma stock plunges to 52-week low of $0.5 - Investing.com
Vor Biopharma CMO resigns to pursue new opportunity By Investing.com - Investing.com Australia
Vor Biopharma’s Chief Medical Officer Resigns - TipRanks
Vor Biopharma CMO resigns to pursue new opportunity - Investing.com
Vor Bio Advances in Clinical Trials and Secures Funding - TipRanks
Vor Biopharma stock plunges to 52-week low of $0.63 - Investing.com
Vor Biopharma stock plunges to 52-week low of $0.63 By Investing.com - Investing.com South Africa
Zenas BioPharma, Inc. Announcement: If You Have Suffered - GlobeNewswire
Virtu Financial LLC Makes New $60,000 Investment in Vor Biopharma Inc. (NYSE:VOR) - Defense World
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely - Yahoo Finance
Vor Biopharma Inc. (NYSE:VOR) Receives Average Rating of “Buy” from Analysts - Defense World
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering - GlobeNewswire
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress By Investing.com - Investing.com Canada
Vor Biopharma’s SWOT analysis: stock outlook amid AML treatment progress - Investing.com India
Vor Biopharma stock holds $6 target, Market Outperform rating By Investing.com - Investing.com South Africa
Vor Biopharma stock holds $6 target, Market Outperform rating - Investing.com India
Citizens JMP Reiterates Market Outperform Rating on Vor Biopharma, Inc. (VOR) - StreetInsider
Stifel Nicolaus Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock Price - Defense World
Oppenheimer Reiterates “Outperform” Rating for Vor Biopharma (NYSE:VOR) - Defense World
Wedbush Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR) - Defense World
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Skye Bioscience (SKYE) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Stifel cuts Vor Biopharma stock target to $5, maintains Buy rating By Investing.com - Investing.com South Africa
Vor Biopharma, Inc. (VOR) PT Lowered to $5 at Stifel - StreetInsider.com
Vor Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update - MarketScreener
Vor Biopharma (VOR) Files $350M Mixed Shelf - StreetInsider.com
Vor Biopharma Inc. SEC 10-K Report - TradingView
Vor Biopharma Inc. (VOR) reports earnings - Quartz
Vor Biopharma revises stock option exercise prices - MSN
Vor Biopharma Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
BenitecAnother Biopharma Rocket - Barchart
Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ - GlobeNewswire
Vor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of “Buy” by Analysts - Defense World
Vor Biopharma: Short On Cash, Too Much Uncertainty For Now (VOR) - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq - ACCESS Newswire
Vor biopharma chief medical officer sells $3,162 in stock By Investing.com - Investing.com Canada
Vor Biopharma Inc Azioni (VOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):